Mitomycin‐C and megestrol acetate in treatment of breast cancer refractory to hormonal and combination chemotherapy

Aman U. Buzdar, Charles K. Tashima, George R. Blumenschein, Gabriel N. Hortobagyi, Hwee‐Yong ‐Y Yap, Allan Norman Krutchik, Gerald P. Bodey, Robert B. Livingston

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Fifty patients with breast cancer refractory to endocrine manipulation and/or combination chemotherapy were treated with mitomycin‐C 20 mg/m2 I.V. every 4–6 weeks and megestrol acetate 160 mg daily. Of 48 evaluable patients, 4% achieved complete remission (CR), 23% had partial remission (PR). Median duration of response for CR and PR was 7 months. Non‐responders had a median survival of 2 months. The difference in survival of responders (both CR and PR) and non‐responders was statistically significant at p<0.01 level. Attenuated doses of mitomycin‐C were administered at increasing intervals due to cumulative myelosuppressive toxicity.

Original languageEnglish (US)
Pages (from-to)392-395
Number of pages4
JournalCancer
Volume41
Issue number2
DOIs
StatePublished - Jan 1 1978

Fingerprint

Megestrol Acetate
Combination Drug Therapy
Breast Neoplasms
Survival
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Mitomycin‐C and megestrol acetate in treatment of breast cancer refractory to hormonal and combination chemotherapy. / Buzdar, Aman U.; Tashima, Charles K.; Blumenschein, George R.; Hortobagyi, Gabriel N.; Yap, Hwee‐Yong ‐Y; Krutchik, Allan Norman; Bodey, Gerald P.; Livingston, Robert B.

In: Cancer, Vol. 41, No. 2, 01.01.1978, p. 392-395.

Research output: Contribution to journalArticle

Buzdar, Aman U. ; Tashima, Charles K. ; Blumenschein, George R. ; Hortobagyi, Gabriel N. ; Yap, Hwee‐Yong ‐Y ; Krutchik, Allan Norman ; Bodey, Gerald P. ; Livingston, Robert B. / Mitomycin‐C and megestrol acetate in treatment of breast cancer refractory to hormonal and combination chemotherapy. In: Cancer. 1978 ; Vol. 41, No. 2. pp. 392-395.
@article{9c02361d201f4582bafa7e083e7f404b,
title = "Mitomycin‐C and megestrol acetate in treatment of breast cancer refractory to hormonal and combination chemotherapy",
abstract = "Fifty patients with breast cancer refractory to endocrine manipulation and/or combination chemotherapy were treated with mitomycin‐C 20 mg/m2 I.V. every 4–6 weeks and megestrol acetate 160 mg daily. Of 48 evaluable patients, 4{\%} achieved complete remission (CR), 23{\%} had partial remission (PR). Median duration of response for CR and PR was 7 months. Non‐responders had a median survival of 2 months. The difference in survival of responders (both CR and PR) and non‐responders was statistically significant at p<0.01 level. Attenuated doses of mitomycin‐C were administered at increasing intervals due to cumulative myelosuppressive toxicity.",
author = "Buzdar, {Aman U.} and Tashima, {Charles K.} and Blumenschein, {George R.} and Hortobagyi, {Gabriel N.} and Yap, {Hwee‐Yong ‐Y} and Krutchik, {Allan Norman} and Bodey, {Gerald P.} and Livingston, {Robert B.}",
year = "1978",
month = "1",
day = "1",
doi = "10.1002/1097-0142(197802)41:2<392::AID-CNCR2820410202>3.0.CO;2-7",
language = "English (US)",
volume = "41",
pages = "392--395",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Mitomycin‐C and megestrol acetate in treatment of breast cancer refractory to hormonal and combination chemotherapy

AU - Buzdar, Aman U.

AU - Tashima, Charles K.

AU - Blumenschein, George R.

AU - Hortobagyi, Gabriel N.

AU - Yap, Hwee‐Yong ‐Y

AU - Krutchik, Allan Norman

AU - Bodey, Gerald P.

AU - Livingston, Robert B.

PY - 1978/1/1

Y1 - 1978/1/1

N2 - Fifty patients with breast cancer refractory to endocrine manipulation and/or combination chemotherapy were treated with mitomycin‐C 20 mg/m2 I.V. every 4–6 weeks and megestrol acetate 160 mg daily. Of 48 evaluable patients, 4% achieved complete remission (CR), 23% had partial remission (PR). Median duration of response for CR and PR was 7 months. Non‐responders had a median survival of 2 months. The difference in survival of responders (both CR and PR) and non‐responders was statistically significant at p<0.01 level. Attenuated doses of mitomycin‐C were administered at increasing intervals due to cumulative myelosuppressive toxicity.

AB - Fifty patients with breast cancer refractory to endocrine manipulation and/or combination chemotherapy were treated with mitomycin‐C 20 mg/m2 I.V. every 4–6 weeks and megestrol acetate 160 mg daily. Of 48 evaluable patients, 4% achieved complete remission (CR), 23% had partial remission (PR). Median duration of response for CR and PR was 7 months. Non‐responders had a median survival of 2 months. The difference in survival of responders (both CR and PR) and non‐responders was statistically significant at p<0.01 level. Attenuated doses of mitomycin‐C were administered at increasing intervals due to cumulative myelosuppressive toxicity.

UR - http://www.scopus.com/inward/record.url?scp=0017801135&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017801135&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(197802)41:2<392::AID-CNCR2820410202>3.0.CO;2-7

DO - 10.1002/1097-0142(197802)41:2<392::AID-CNCR2820410202>3.0.CO;2-7

M3 - Article

C2 - 630529

AN - SCOPUS:0017801135

VL - 41

SP - 392

EP - 395

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 2

ER -